A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
ASH and SABCS approach.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
The project has priority review, but deaths could raise eyebrows.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
An in vivo Car-T produced a 100% response rate – in three patients.
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
